Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016.
immunocompromised host
infection control
molecular epidemiology
single room contact precautions
transmission
vancomycin-resistant enterococci
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
entrez:
14
1
2022
pubmed:
15
1
2022
medline:
9
3
2022
Statut:
ppublish
Résumé
BackgroundEvidence supporting the effectiveness of single-room contact precautions (SCP) in preventing in-hospital acquisition of vancomycin-resistant enterococci (haVRE) is limited.AimWe assessed the impact of SCP on haVRE and their transmission.MethodsWe conducted a prospective, multicentre cohort study in German haematological/oncological departments during 2016. Two sites performed SCP for VRE patients and two did not (NCP). We defined a 5% haVRE-risk difference as non-inferiority margin, screened patients for VRE, and characterised isolates by whole genome sequencing and core genome MLST (cgMLST). Potential confounders were assessed by competing risk regression analysis.ResultsWe included 1,397 patients at NCP and 1,531 patients at SCP sites. Not performing SCP was associated with a significantly higher proportion of haVRE; 12.2% (170/1,397) patients at NCP and 7.4% (113/1,531) patients at SCP sites (relative risk (RR) 1.74; 95% confidence interval (CI): 1.35-2.23). The difference (4.8%) was below the non-inferiority margin. Competing risk regression analysis indicated a stronger impact of antimicrobial exposure (subdistribution hazard ratio (SHR) 7.46; 95% CI: 4.59-12.12) and underlying disease (SHR for acute leukaemia 2.34; 95% CI: 1.46-3.75) on haVRE than NCP (SHR 1.60; 95% CI: 1.14-2.25). Based on cgMLST and patient movement data, we observed 131 patient-to-patient VRE transmissions at NCP and 85 at SCP sites (RR 1.76; 95% CI: 1.33-2.34).ConclusionsWe show a positive impact of SCP on haVRE in a high-risk population, although the observed difference was below the pre-specified non-inferiority margin. Importantly, other factors including antimicrobial exposure seem to be more influential.
Identifiants
pubmed: 35027104
doi: 10.2807/1560-7917.ES.2022.27.2.2001876
pmc: PMC8759111
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA. 2013 Oct 16;310(15):1571-80
pubmed: 24097234
J Clin Microbiol. 2016 Dec;54(12):2874-2881
pubmed: 27558178
Am J Infect Control. 2009 Mar;37(2):85-93
pubmed: 19249637
Infection. 2019 Feb;47(1):7-11
pubmed: 30178076
Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28
pubmed: 12019066
MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13
pubmed: 7565541
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jan;47(1):51-61
pubmed: 15205824
Lancet Infect Dis. 2019 Apr;19(4):410-418
pubmed: 30858014
N Engl J Med. 2011 Apr 14;364(15):1407-18
pubmed: 21488763
JAMA Intern Med. 2019 Nov 1;179(11):1501-1506
pubmed: 31424489
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62
pubmed: 30895215
N Engl J Med. 2000 Dec 28;343(26):1925-32
pubmed: 11136263
Infection. 2012 Dec;40(6):613-9
pubmed: 22665143
J Clin Microbiol. 2015 Dec;53(12):3788-97
pubmed: 26400782
J Hosp Infect. 2011 Mar;77(3):282-3
pubmed: 21288596
Open Forum Infect Dis. 2019 Mar 15;6(4):ofz139
pubmed: 31024976
Antimicrob Agents Chemother. 1996 Jun;40(6):1526-30
pubmed: 8726031
Antimicrob Agents Chemother. 2013 Jan;57(1):49-55
pubmed: 23070173
Infection. 2014 Dec;42(6):1013-22
pubmed: 25143193
Infect Control Hosp Epidemiol. 2011 May;32(5):490-6
pubmed: 21515980
Antimicrob Resist Infect Control. 2018 Apr 24;7:54
pubmed: 29760912
Am J Infect Control. 2018 Mar;46(3):333-340
pubmed: 29031432
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30782988
J Antimicrob Chemother. 2019 Jul 1;74(7):1776-1785
pubmed: 30929020
J Hosp Infect. 2010 Oct;76(2):97-102
pubmed: 20619929
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026